Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Past 10 year's financial track record analysis by Moneyworks4me indicates that Remus Pharmaceuticals Ltd is a average quality company.
The key valuation ratios of Remus Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Remus Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|
| ROCE % ⓘ | 29.5% | 32.9% | 66.2% | 48.6% | - |
| Value Creation Index ⓘ | 1.1 | 1.4 | 3.7 | 2.5 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||
| Sales ⓘ | 11.9 | 18.4 | 24.7 | 45 | 45 |
| Sales YoY Gr. | - | 54.5% | 34.1% | 82.3% | - |
| Adj EPS ⓘ | 6.7 | 9.1 | 32.8 | 74.3 | 57.7 |
| YoY Gr. | - | 36.1% | 259% | 126.8% | - |
| BVPS (₹) ⓘ | 20.2 | 30.5 | 65.8 | 176.4 | 453.6 |
| Adj Net Profit ⓘ | 0.7 | 0.9 | 3.3 | 8.1 | 8 |
| Cash Flow from Ops. ⓘ | 1.3 | 2.8 | 5 | 5.3 | - |
| Debt/CF from Ops. ⓘ | 0.3 | 0.1 | 0 | 1.5 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | 55.7% | 82.3% | ||||
| Adj EPS ⓘ | NA | NA | 122.9% | 126.8% | ||||
| BVPSⓘ | NA | NA | 105.9% | 168.1% | ||||
| Share Price | - | - | - | - | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|
| Return on Equity % ⓘ | 33.2 | 36 | 68.1 | 62.7 | 18.3 |
| Op. Profit Mgn % ⓘ | 3.3 | 4.1 | 16.7 | 23.4 | NAN |
| Net Profit Mgn % ⓘ | 5.6 | 5 | 13.3 | 17.9 | 18.9 |
| Debt to Equity ⓘ | 0.2 | 0.1 | 0 | 0.4 | - |
| Working Cap Days ⓘ | 0 | 132 | 155 | 79 | 0 |
| Cash Conv. Cycle ⓘ | 0 | -7 | -33 | -14 | 0 |
Sales growth is growing at healthy rate in last 3 years 55.74%
Net Profit is growing at healthy rate in last 3 years 122.92%
Return on Equity has declined versus last 3 years average to 18.30%
Sales growth is not so good in last 4 quarters at 0.00%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 57.7 | - |
| TTM Sales (₹ Cr.) | 45 | - |
| BVPS (₹.) ⓘ | 453.6 | - |
| Reserves (₹ Cr.) ⓘ | 65 | - |
| P/BV ⓘ | 18.22 | - |
| PE ⓘ | 143.22 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 0.00 / 0.00 |
| All Time Low / High (₹) | - / - |
| Market Cap (₹ Cr.) | 1,218 |
| Equity (₹ Cr.) | 1.5 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 78.3 |
| Pledged * | 0.00 | 0.00 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|
| Sales | 12 | 18 | 25 | 45 |
| Operating Expenses ⓘ | 12 | 18 | 21 | 34 |
| Manufacturing Costs | 0 | 0 | 1 | 1 |
| Material Costs | 7 | 11 | 12 | 21 |
| Employee Cost | 3 | 3 | 3 | 5 |
| Other Costs ⓘ | 2 | 3 | 4 | 6 |
| Operating Profit ⓘ | 0 | 1 | 4 | 11 |
| Operating Profit Margin (%) | 3.3% | 4.1% | 16.7% | 23.4% |
| Other Income ⓘ | 1 | 1 | 1 | 2 |
| Interest ⓘ | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 0 | 0 | 0 | 0 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 1 | 1 | 5 | 11 |
| Tax ⓘ | 0 | 0 | 1 | 3 |
| Profit After Tax | 1 | 1 | 3 | 9 |
| PAT Margin (%) | 6.8% | 5.6% | 13.9% | 18.9% |
| Adjusted EPS (₹) | 8.1 | 10.3 | 34.3 | 78.4 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 3% |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 2 | 3 | 7 | 19 | ||||||
| Share Capital ⓘ | 0 | 0 | 1 | 1 | ||||||
| Reserves ⓘ | 2 | 3 | 6 | 18 | ||||||
| Minority Interest | 0 | 0 | 0 | 0 | ||||||
| Debt | 0 | 0 | 0 | 8 | ||||||
| Long Term Debt | 0 | 0 | 0 | 7 | ||||||
| Short Term Debt | 0 | 0 | 0 | 1 | ||||||
| Trade Payables | 1 | 5 | 5 | 4 | ||||||
| Others Liabilities ⓘ | 2 | 3 | 4 | 4 | ||||||
| Total Liabilities ⓘ | 5 | 11 | 16 | 35 | ||||||
Fixed Assets | ||||||||||
| Gross Block | 1 | 1 | 1 | 3 | ||||||
| Accumulated Depreciation | 0 | 0 | 0 | 1 | ||||||
| Net Fixed Assetsⓘ | 1 | 0 | 0 | 3 | ||||||
| CWIP ⓘ | 0 | 0 | 0 | 0 | ||||||
| Investmentsⓘ | 0 | 0 | 3 | 21 | ||||||
| Inventories | 0 | 1 | 2 | 0 | ||||||
| Trade Receivables | 2 | 4 | 3 | 5 | ||||||
| Cash Equivalents | 1 | 1 | 1 | 3 | ||||||
| Others Assetsⓘ | 2 | 5 | 7 | 3 | ||||||
| Total Assets ⓘ | 5 | 11 | 16 | 35 | ||||||
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 1 | 3 | 5 | 5 |
| PBT ⓘ | 1 | 1 | 5 | 11 |
| Adjustment ⓘ | 0 | 0 | 0 | 0 |
| Changes in Working Capital ⓘ | 0 | 2 | 2 | -3 |
| Tax Paid ⓘ | 0 | 0 | -1 | -3 |
| Cash Flow From Investing Activity ⓘ | -1 | -3 | -5 | -15 |
| Capex | -1 | 0 | 0 | -3 |
| Net Investments | 0 | 0 | -3 | -18 |
| Others ⓘ | 0 | -3 | -1 | 5 |
| Cash Flow From Financing Activityⓘ | 0 | 0 | 0 | 12 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 4 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 7 |
| Interest Paid ⓘ | 0 | 0 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 |
| Others ⓘ | 0 | 0 | 0 | 1 |
| Net Cash Flow ⓘ | 1 | 0 | 0 | 2 |
| PARTICULARS | Mar'20 | Mar'21 | Mar'22 | Mar'23 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 40.17 | 40.49 | 71.37 | 66.14 | ||||||
| ROCE (%) | 47.76 | 48.84 | 93.13 | 68.82 | ||||||
| Asset Turnover Ratio | 2.26 | 2.26 | 1.84 | 1.79 | ||||||
| PAT to CFO Conversion(x) | 1 | 3 | 1.67 | 0.56 | Working Capital Days | |||||
| Receivable Days | 50 | 52 | 48 | 31 | ||||||
| Inventory Days | 13 | 16 | 20 | 8 | ||||||
| Payable Days | 68 | 103 | 146 | 70 | ||||||
The company was originally incorporated as ‘Remus Pharmaceuticals Private Limited’ as a private limited company, under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat. Later on, pursuant to a special resolution passed by its shareholders in the Extra-Ordinary General Meeting held on January 02, 2023, the company was converted from a private limited company to public limited company and consequently, the name of the company was changed to ‘Remus Pharmaceuticals Limited’, and a fresh certificate of incorporation dated January 06, 2023 was issued to the company by the Registrar of Companies, Ahmedabad.
The company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries. Having cultivated strong and dependable customer relationships ranging from Generic distributors, regional distributors and Multinational distributors to Hospitals and Clinics through a responsive distribution network, its clients are spread in various countries. It looks forward to form long lasting relationships that enhance the lives of its patients.
The company is majorly engrossed in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical finished formulations and products. Depending upon business requirements, it gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing. Such manufacturing is on principle to principle basis. It has its presence through registered and/or under registration products in countries namely Bhutan, Bolivia, Chile, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Honduras, Jamaica, Kuwait, Madagascar, Malaysia, Hong Kong, Myanmar, Panama, Trinidad and Tobago, Uzbekistan, Venezuela, Vietnam etc. It deals in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet.
Business area of the company
The company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient).
Products of the company
History and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
